IrbesartanThird Party Manufacturing in India

Irbesartan works by selectively and competitively blocking the binding of angiotensin II to the angiotensin II type 1 receptor, which is the primary receptor responsible for mediating the classical pressor effects of the renin-angiotensin-aldosterone system. Angiotensin II is a potent vasoconstrictor that also stimulates aldosterone secretion, promotes sodium and water retention, and induces vascular smooth muscle cell proliferation and hypertrophy. By antagonising the AT1 receptor, Irbesartan prevents angiotensin II from exerting these effects, leading to relaxation of arterial and venous smooth muscle, dilation of peripheral blood vessels, and a subsequent reduction in systemic vascular resistance and arterial blood pressure. Unlike angiotensin-converting enzyme inhibitors, Irbesartan does not inhibit the degradation of bradykinin and therefore does not produce the dry cough that often limits ACE inhibitor therapy. The drug is highly selective for the AT1 receptor subtype over the AT2 receptor, leaving the AT2 receptor free to be stimulated by unopposed angiotensin II which may contribute to favourable vasodilatory and anti-proliferative effects. Irbesartan also demonstrates dose-dependent reductions in plasma aldosterone levels, contributing to its antihypertensive effect, and provides consistent 24-hour blood pressure control with once-daily dosing. The drug has additional renoprotective effects beyond blood pressure lowering, including reduction of intraglomerular pressure and proteinuria, making it particularly valuable in hypertensive patients with diabetic nephropathy.

Irbesartan is a widely prescribed angiotensin II receptor blocker used primarily for the management of hypertension and the protection of renal function in patients with type 2 diabetes. It offers excellent tolerability with a side effect profile comparable to placebo, making it a preferred first-line or add-on agent in most hypertension treatment guidelines. The drug is available in three strengths of 75mg, 150mg, and 300mg tablets, allowing for flexible dose titration from a starting dose to a maintenance dose for optimal blood pressure control.

Therapeutic Uses

• Essential Hypertension: Irbesartan is indicated for the treatment of essential hypertension in adults, either as monotherapy or in combination with other antihypertensive agents such as thiazide diuretics and calcium channel blockers, providing sustained 24-hour blood pressure reduction.
• Diabetic Nephropathy: The drug is indicated for the treatment of renal disease in patients with type 2 diabetes and hypertension, as it slows the progression of nephropathy by reducing proteinuria and preserving glomerular filtration rate.
• Hypertensive Nephropathy: Irbesartan provides renoprotective effects in non-diabetic chronic kidney disease patients with hypertension, reducing the risk of progression to end-stage renal disease.
• Heart Failure: Although not a primary indication, Irbesartan is used in the management of heart failure with preserved ejection fraction, particularly in patients who cannot tolerate ACE inhibitors.

Why Manufacturers Choose Irbesartan

Irbesartan is one of the most prescribed ARBs globally, with particularly strong demand in the Indian market where hypertension prevalence is rising rapidly. Indian manufacturers produce Irbesartan across all three strengths, and the molecule is also widely formulated as a fixed-dose combination with hydrochlorothiazide. The API manufacturing base in India is well established, and the molecule offers good margins across both domestic PCD franchise channels and export markets in Africa, the Middle East, and Southeast Asia. Its favourable tolerability profile compared to ACE inhibitors makes it a popular choice for PCD franchise operators looking to build a comprehensive antihypertensive portfolio.